NICE approves routine use of drug combination for advanced breast cancer


23 September 2022 - Another life-extending drug combination for some people with advanced breast cancer will now be available for routine use in the NHS following its approval by NICE in final draft guidance published today.

Palbociclib (Ibrance, Pfizer) when given with fulvestrant, is recommended for adults with  hormone receptor positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer who have already had hormone therapy.

Read NICE press release

Michael Wonder

Posted by:

Michael Wonder